In a move reminiscent of past trade disputes, China appears to have launched a price war on key active pharmaceutical ...

US drug developer Nektar Therapeutics saw its shares rise 9% to $55.66 following release of new data from the ongoing REZOLVE ...

South Korean biotech CorestemChemon (Kosdaq: 166480) has shared Phase III ALSummit trial findings for its autologous stem ...

Portuguese venture firm Biovance Capital Partners has led a series A financing for Mondego Bio, joined by US investors ...

California, USA-based liver specialist 89bio saw its shares rocket more than 83% to $14.83 in pre-market activity on the news ...

US biotech Biogen has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics, a company the ...

US biotech Arvinas today provided an update on its 2021 collaboration with pharma giant Pfizer for the co-development of ...

Regeneron Pharmaceuticals has announced the primary endpoint was met in the Phase III OPTIMA trial investigating garetosmab ...

The European Commission (EC) has granted marketing authorization for US biotech major Biogen’s Zurzuvae (zuranolone) to treat ...

The biologics supply chain has shifted from a technical backwater into a political and regulatory battleground. Vectors, ...

The European Court of Auditors has warned that Europe still lacks a reliable system to prevent and manage medicine shortages, ...

US drugmaker Eli Lilly’s battle for dominance of the GLP-1 weight loss and diabetes market with Novo Nordisk is becoming an epic.